ECO Animal Health Group plc (AIM:EAH)

Market Cap	41.67M
Revenue (ttm)	84.60M
Net Income (ttm)	658.00K
Shares Out	67.76M
EPS (ttm)	0.01
PE Ratio	64.05
Forward PE	34.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,007
Average Volume	50,254
Open	60.66
Previous Close	61.50
Day's Range	60.66 - 62.90
52-Week Range	50.00 - 133.70
Beta	0.03
RSI	45.57
Earnings Date	Jul 10, 2025

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, lices, and mange in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1972
• Employees: 227
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EAH

Financial Performance

In 2023, ECO Animal Health Group's revenue was 89.42 million, an increase of 4.82% compared to the previous year's 85.31 million. Earnings were 1.05 million, an increase of 3.97%.